These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28377205)

  • 21. National Working Group Meeting on ALK diagnostics in lung cancer.
    Cooper W; Fox S; O'Toole S; Morey A; Frances G; Pavlakis N; O'Byrne K; Dettrick A; Leong T; Rathi V; Spagnolo D; Hemmings C; Singh M; Moffat D; Tsao MS; Wilner K; Buller R; Pitman Lowenthal S; Arifeen S; Binko J; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():11-7. PubMed ID: 24673736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
    Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
    Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
    Gottschling S; Herpel E; Eberhardt WE; Heigener DF; Fischer JR; Köhne CH; Kortsik C; Kuhnt T; Muley T; Meister M; Bischoff HG; Klein P; Moldenhauer I; Schnabel PA; Thomas M; Penzel R
    Lung Cancer; 2012 Jul; 77(1):183-91. PubMed ID: 22483783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Routine implementation of EGFR mutation testing in clinical practice in Flanders: 'HERMES' project.
    Janssens A; De Droogh E; Lefebure A; Kockx M; Pauwels P; Germonpre P; van Meerbeeck JP
    Acta Clin Belg; 2014 Apr; 69(2):92-7. PubMed ID: 24724747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analytic inquiry: Molecular testing in lung cancer.
    Zakowski MF
    Cancer Cytopathol; 2017 Jun; 125(S6):470-476. PubMed ID: 28609002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of advanced non-small-cell lung cancer with driver mutations].
    Tessmer A; Kollmeier J
    Dtsch Med Wochenschr; 2015 Mar; 140(5):323-8. PubMed ID: 25734673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
    Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
    Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and Amplifications in Non-Small Cell Lung Carcinomas.
    Liu C; Pepper K; Hendrickson H; Cagle PT; Portier BP
    Arch Pathol Lab Med; 2016 Jul; 140(7):690-3. PubMed ID: 26599807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
    Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
    Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.
    Leary AF; Castro DG; Nicholson AG; Ashley S; Wotherspoon A; O'Brien ME; Popat S
    Eur J Cancer; 2012 Jan; 48(1):61-7. PubMed ID: 22036089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer.
    Kirita K; Izumo T; Matsumoto Y; Hiraishi Y; Tsuchida T
    Lung; 2016 Jun; 194(3):371-8. PubMed ID: 26951235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
    Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
    Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.
    Krawczyk P; Chorostowska-Wynimko J; Dziadziuszko R; Jassem J; Krzakowski M; Langfort R; Puacz E; Wasąg B; Wojas-Krawczyk K
    Pneumonol Alergol Pol; 2014; 82(5):437-44. PubMed ID: 25133812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.